# Tern FY 2024 Results: Core portfolio grows ARR, cuts costs by 30%

- Link: https://www.directorstalkinterviews.com/tern-fy-2024-results-core-portfolio-grows-arr-cuts-costs-by-30/4121200356
- Published: 2025-06-05T07:11:17+01:00
- Author: Amilia Stone

**[Tern Plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)** (
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)), the
investment company specialising in supporting high growth, early-stage, disruptive
Internet of Things technology businesses, has announced its audited results for 
the year ended 31 December 2024.

**Chairman’s Statement**

While market conditions remained challenging, I am pleased to report that 2024 was
a year of meaningful progress for Tern. Our core portfolio continues to mature and
demonstrate strength, and we remain firmly committed to delivering long-term value
to our shareholders.

Tern offers investors a rare opportunity: the ability to hold shares in an AIM-quoted
venture capital company focused on early-stage, high-growth technology businesses-
companies typically inaccessible to most AIM retail investors. In many ways, our
shareholders operate as Limited Partners in a traditional venture capital fund, 
but with the added advantage of daily liquidity and no obligation to contribute 
additional capital.

We have built a focused, high-potential portfolio operating in sectors poised for
substantial growth. The Tern team actively works with our portfolio companies to
drive value through hands-on support, strategic development, and, at the appropriate
stage, targeted exits aimed at maximising shareholder returns.

In addition to the intrinsic value of the portfolio, our strategy is built around
delivering shareholder returns through three core pillars:

·    **Capital Distribution** via an appropriate method, when exits deliver sufficient
proceeds.

·    **Capital growth** through the successful commercial execution of our portfolio
companies.

·    **Diversification** by providing exposure to a wide array of transformative
technology businesses typically out of reach for individual investors.

**Portfolio Review**

**Device Authority**

In December 2024 DA received the second fundraising tranche from industry specialist
investor, Ten Eleven Ventures, of US$3.3m, at the same price as the first tranche
provided in December 2023. The funds are being used by DA to advance product development,
expanding its North American footprint and enhancing its Identity and Access Management(
IAM) solutions for the Internet of Things (IoT).

DA’s KeyScaler® platform, focused on automotive, medical and industrial sectors 
enabling ‘zero trust’ security for the IoT, has been selected by several major enterprises.
DA acquired new customers in 2024, with existing key clients gearing up for mass
production, utilising the platform.

With a strong presence in the UK, DA also has a successful ‘go to market’ in the
US which has delivered three major customer wins in 2025. The total addressable 
market is large and growing, with cybercrime estimated by Cybersecurity Ventures
to be the third largest economy in the world, with a fragmented industry. DA’s annual
recurring revenue (ARR) rose 10% year over year.

In March 2025 DA announced its that it had joined forces with Microsoft and CyberArk
to deliver a secure IoT solution for manufacturing based on the National Institute
of Standards and Technology’s (NIST) latest framework. DA now plays a crucial role
as a Microsoft IoT and Operational Technology (OT) security partner for Microsoft’s
Manufacturing Industry Reference Architecture.

Initial client wins are expanding into further orders leveraging KeyScaler®. One
of DA’s existing clients, a global leading automotive components provider, is scaling
production to more factories as part of its Identity management process.

DA’s modularised licence platform KSaaS (KeyScaler Software as a Service) has achieved
over 16 million machine identity authentications worldwide, demonstrating the platform’s
scalability and its ability to secure IoT devices across diverse industries.

**FundamentalVR**

FVR provide a software simulation environment that allows surgeons’ accuracy to 
be measured objectively for the first time, with a mission to revolutionise surgical
education globally.

Despite 2024 being tough in terms of macro conditions and customer restructuring,
FVR expanded its relationships with existing logos. Customer growth was strong, 
including very important strategic alliances with Apple, Meta and Logitech, with
Artificial Intelligence (AI) being used in different ways.

Apple’s and Meta’s continued expansion of activity in the metaverse space provide
significant interest and opportunities for the company.

A significant milestone in Q4 2024 was the launch of The American Academy of Ophthalmology
VR Education programme on the platform.

In December 2024, the company was named ‘Best Surgery Training VR Technology Company
2024’ in the Global Excellence Awards by GHP Magazine, and the technology is vendor/
hardware agnostic.

FVR was recognised as one of Fast Company’s ‘Most Innovative Companies of 2025’.
This honour highlights their groundbreaking work in virtual reality, artificial 
intelligence, and haptic technology, which is transforming surgical training and
medical education.

**Talking Medicines**

TM’s revenues and annual recurring revenues both grew year on year, and with much
improved gross margins. Operating expenses fell sharply in the year. TM has secured
partnerships and signed contracts with multiple US based healthcare advertising 
agencies that serve pharmaceutical companies.

2024 was a breakthrough year, and the Board sees significant potential in TM’s next
phase of growth, with its customers entrusting over 2.9 million pieces of data to
TM to date. Already at the forefront of AI, the company’s Drug-GPT stands apart 
as a specialised ‘Curated Large Language Model’.

The prescription drug market in the US alone is huge, and the cost of poor medical
adherence is estimated by the PAN Foundation to be US$525bn, with US$30bn spent 
on marketing to address this. TM is well established in an AI category that is operating
in a fast growing and large market, operating in Machine Learning and Natural Language
Processing.

**Sure Valley Ventures Enterprise Capital LP**

Tern continues to fulfil its commitment to invest up to £5m in SVV2 over the 10-
year life of SVV2, entered into in March 2022. During 2024, Tern invested a further
£0.5m in SVV2 to support their five further investments.

In addition, we added a modest investment in Sure Ventures plc to our portfolio 
post the year end, in January 2025, which has a 25.9% interest in Sure Valley Ventures
Fund (“SVV1”) and an approximate 6% interest in SVV2, providing exposure and potential
upside to additional exciting technology businesses.

This ‘fund of funds’ approach, in addition to our direct investments is, I believe,
important for a number of reasons. Crucially it reduces the inherent risk associated
with a concentrated portfolio and the uncertainty as to when value will be realised.
Additionally, it allows our operating costs to be spread across a wider portfolio,
we have the potential to recoup some costs through providing assistance to the companies
held by these funds, we have the potential to receive exit proceeds earlier and 
there is the potential for synergy benefits for our direct portfolio companies from
working with the fund’s underlying investee companies.

**Wyld Networks**

In 2024, Wyld faced financial difficulties and raised capital via a rights issue
on terms we believe were detrimental to existing shareholders. Tern did not participate
in the rights issue, resulting in significant dilution. As a result of Wyld’s IPO
in 2021, Tern no longer plays a day-to-day role in Wyld’s governance and had no 
influence over the fundraising process. Nevertheless, of the total capital Tern 
invested in Wyld, a substantial portion has been returned. We continue to monitor
developments closely.

**InVMA Limited**

It was disappointing that in March 2024 Konektio entered administration. Tern had
previously announced on 8 November 2023 that the Company had decided not to invest
further in Konektio and following this decision, 75% of Tern’s holding in Konektio
was transferred into a valueless class of Konektio deferred shares, as announced
on 29 November 2023. Tern held approximately 8.8% of Konektio’s equity at the time
of administration and this holding had an unaudited book valuation of £222,624 as
at 31 December 2023. Following Konektio entering administration, the Tern Directors
concluded that it is unlikely that any value will be realisable from Tern’s holding
in Konektio and Tern’s holding in Konektio is therefore now be held at zero value.

**Outlook**

Our core portfolio companies, Device Authority, FundamentalVR and Talking Medicines
are thriving – despite a difficult environment for early-stage technology funding.
They are delivering strong commercial traction, attracting global partners and investors,
and we believe maturing into leaders in their respective markets.

Continued progress will require ongoing investment. To preserve our influence and
potential return at exit, we must be in a position to support our portfolio through
growth funding rounds – particularly against a backdrop of almost abundant private
capital. As such, Tern having access to capital and flexibility to issue new shares
remain strategically important.

Our model – focusing on seed to Series B rounds – positions us to benefit from significant
upside potential as companies enter Series C and beyond. But this value can only
be realised if we retain sufficient equity, which requires sustained support through
follow-on funding.

Tern is also exceptionally well placed to benefit from growing interest in early-
stage software and the generative AI space. Unlike passive capital, we invest time,
expertise, and strategic insight into our portfolio companies. This approach has
been critical in helping our portfolio companies raise growth capital and scale 
operations, particularly in the United States, the world’s most dynamic technology
market.

We continue to operate with a lean structure. Administration costs were reduced 
by 40% following the board and management restructuring in August 2023, and further
reduced by 30% in 2024 year over year. We charge nominal management fees to our 
core portfolio companies, choosing instead to focus all resources on building long-
term value.

In 2024, our management team, including Bruce Leith and Al Sisto, have once again
proven the value of their deep experience and entrepreneurial track record. Our 
involvement with SVV2 also continues to open new avenues for income and value creation,
such as the appointment of Bruce Leith as Executive Chairman of Purple Transform,
with Tern receiving the related service fees.

We also welcomed two new non-executive directors, Jane McCracken and Iain Ross, 
whose contributions are already shaping Tern’s strategic direction. I would like
to thank our retiring directors, Alan Howarth and Sarah Payne, for their wisdom 
and service during their tenure.

An investment in Tern is a gateway to early-stage technology investing, offering
access to what we believe are exceptional companies often beyond the reach of private
investors. Our mission is clear: to support these businesses through their most 
critical stages, build them into market leaders, and deliver long-term capital gains
for our shareholders.

We thank shareholders for their continued trust and support and remain focused on
achieving the best possible return on their investment.

**Ian Ritchie CBE, FREng, FRSE**

**Chairman**

**Financial Review**

2024 has been a dynamic and promising year for the portfolio as we continue to invest
in the rapidly evolving Internet of Things (“IoT”) and artificial intelligence (“
AI”) sectors. Driven by increasing enterprise adoption, advancements in machine 
learning, and the growing need for automation, our portfolio companies and holdings
are transforming industries at an unprecedented pace. Market trends indicate sustained
growth, with AI- powered solutions enhancing efficiency across healthcare, finance,
and manufacturing, while IoT adoption fuels smarter infrastructure and connected
ecosystems. We believe that our strategic investments have positioned us at the 
forefront of this innovation wave, reinforcing our commitment to unlock the potential
of leading-edge private UK tech companies in order to deliver strong returns to 
our valuable shareholders.

_Statement of Financial Position_

Net assets at 31 December 2024 were £10.7m, a reduction of £1.6m from the net assets
of £12.3m at 31 December 2023. This is principally due to movements in investments
held at fair value through the profit or loss (“FVTPL”) and the significant ongoing
costs of operating as an AIM-quoted company. As noted in the Chairman’s Statement,
the Company has implemented measures to reduce administration costs by 30% this 
year compared to 2023. However, the unavoidable expenses associated with maintaining
Tern’s quoted status will inevitably impact the Company’s net assets on an ongoing
basis.

The decline in the market price of Wyld Networks was the primary driver of the £
2.1m decrease in the fair value of the investment portfolio.

The Company’s cash balance was slightly higher as at 31 December 2024 (£0.4m) compared
to 31 December 2023 (£0.3m). Administration and other operating expenses decreased
by £0.5m year-on-year, largely as a result of the board reorganisation.

Liabilities were £0.25m lower at 31 December 2024 than at the same date in 2023,
primarily due to the partial repayment of the short-term loan. In August 2024, the
Company agreed to an amendment to the short term loan agreement in which the security
requirement attached to the short-term loan facility was removed, and the repayment
period was extended by 12 months to September 2025.

Investments held at FVTPL amounted to £10.7m and represent the Company’s portfolio
of high-growth technology companies. During the year, the fair value of the portfolio
declined by £2.1m, a significantly smaller decrease compared to the £11.1m reduction
recorded in 2023.

_Income Statement and Statement of Comprehensive Income_

The total comprehensive loss for the year was £3.8m (2023: loss of £12.6m), primarily
due to a negative movement in the fair value of investments held at FVTPL of £2.5m
and the £1.2m of operating expenses incurred during the year.

The Company seeks to keep its fees charged to portfolio companies at modest levels,
as the Company’s preference is for capital to instead be reinvested in the portfolio
to drive value creation.

Administration costs decreased to £1.2m in 2024 (2023: £1.7m) as a result of the
board reorganisation which was fully implemented in 2024. Other expenses decreased
to £0.05m in 2024 (2023: £0.2m).

_Statement of Cash Flows_

During the year, £1.1m was used in the Company’s operations, and £0.8m was deployed
within our existing portfolio, via equity and loan investments.

In 2024, £0.3m of the short term loan provided to the Company was repaid (2023: 
£0.1m).

_Key performance indicators_

The Company’s financial Key Performance Indicators (“KPIs”) are centred on increasing
net asset value, enhancing net asset value per share, and achieving consistent revenue
growth across our portfolio. In addition to financial metrics, the Company closely
monitors non-financial KPIs, with a primary focus on the growth in employee numbers
and annual recurring revenue per employee-both key indicators of sustainable commercial
success. These performance metrics are tracked by the Board, with detailed results
outlined below.

_The return on investments_

_Unrealised fair value:_

Wyld Networks: £3k valuation (31 December 2023: £2.4m): The equity valuation has
decreased by £2.4m solely due to the reduction in Wyld Networks’ market capitalisation
to £2.4m at 31 December 2024 (a reduction in share price of 99% since 31 December
2023). Wyld Networks valuation is determined by reference to the appropriate quoted
market price at the reporting date.

Device Authority: £4.3m valuation (31 December 2023: £4.4m): The valuation has decreased
due to the sale of £0.2m of assets held in Device Authority during the year combined
with a small foreign exchange movement.

Konektio: Nil valuation (31 December 2023: Nil): The equity value of Konektio was
written off due to the company entering into administration in March 2024.

FundamentalVR: £3.6m valuation (31 December 2023: £3.6m): The valuation has remained
static.

Talking Medicines: £2.1m valuation (31 December 2023: £2.0m): The valuation has 
increased due to additional funding provided to the company of £0.1m via CLN which
was outstanding at the year end.

DiffusionData: £0.02m valuation (31 December 2023: £0.02m): The investment is valued
at fair value with the price of the most recent valuation taken into account;

SVV2: £0.7m valuation (31 December 2023: £0.3m): The investment is valued at fair
value at the value provided by the SVVUK fund. The fair value increase of £0.4m 
was made up of £0.5m of additional investment, offset by £0.1m decrease in fair 
value as provided by the fund.

The global downturn in technology company valuations and multiples applied to early-
stage businesses was taken into consideration when assessing the fair value of the
portfolio.

The net assets of the Company at 31 December 2024 showed a reduction of £1.6m to
£10.7m (31 December 2023:

£12.3m). The net asset value per ordinary share as at 31 December 2024 decreased
by 1.2p to 2.0p (31 December 2023: 3.2p).

The year-on-year unaudited annual recurring revenue (“ARR”) of our key portfolio
companies (excluding Konektio) decreased by 7% from 2023 to 2024 (increase of 33%
from 2022 to 2023 (excluding Konektio)). This was primarily as a result of a number
of expected revenue opportunities moving from 2024 into 2025.

The Company regularly monitors non-financial Key Performance Indicators (KPIs) as
part of its strategic oversight. These KPIs primarily focus on the growth in employee
numbers within our portfolio and annual recurring revenue (ARR) per employee. We
believe these metrics serve as key leading indicators of future performance and 
reflect our broader impact on stakeholders.

Employees in our key portfolio companies (excluding Konektio) decreased by 45% from
2023 to 2024 (decrease of 11% from 2022 to 2023 (excluding Konektio)), however this
decrease was greater than the decrease in the ARR such that the ARR per employee
increased by 69% from 2023 to 2024 (increase of 50% from 2022 to 2023 (excluding
Konektio)).  The decrease in aggregate employee numbers was primarily as a result
of the reduction in headcount at FundamentalVR as they utilised third party tools,
reducing the need for inhouse capability. The Device Authority and Talking Medicines
teams were stable during the year.

**Investing Policy**

Tern’s investment policy is to invest principally, but not exclusively, in the information
technology sector within Europe. The Directors believe that the Company can invest
in and acquire information technology businesses, improve them by a combination 
of new management and investment, and realise the value created which will be returned
to shareholders. The Company may be either an active investor and acquire control
of a single company or it may acquire non-controlling shareholdings. Once a target
has been identified, additional funds may need to be raised by the Company to complete
a transaction.

The Directors see IT as having considerable growth potential for the foreseeable
future and many of the prospects they have identified are in this sector. The Company
has invested in six investee companies, four of which comprise the principal portfolio
companies and the Directors believe there are further opportunities to invest in
and acquire established IT businesses which have good technology, marquee customers
and could better exploit their assets with the injection of experienced management
and new funds with the intention of creating value for shareholders.

Although the main focus of the investment policy has been on the exploitation of
IT businesses, which the Directors intend to continue; this will not preclude the
Company from considering an investment in suitable projects in other sectors where
the Directors believe that there are high-growth opportunities.

The Directors believe the main driver of success for the Company is the expertise
that can be provided by the Directors to the management involved in its investee
companies and the value creation that the team of people is capable of realising.
The Company is, and intends to continue to be, an active investor. Accordingly, 
it has sought and may seek in future investments, representation on the board of
investee companies.

The new capital available to the Company will be used to support and assist its 
investee companies to grow, where appropriate, and used to locate, evaluate and 
select investment opportunities that offer satisfactory potential capital returns
for shareholders. The Company may require further funds in order to invest further
in its principal portfolio companies and take up these opportunities. It is the 
intention of the Directors to undertake further fundraising if such an opportunity
should arise. The Company’s investments may take the form of equity, debt, or convertible
instruments. Investments may be made in all types of assets falling within the remit
of the Investing Policy and there will be no investment restrictions.

The Directors may consider it appropriate to take an equity interest in any proposed
investment which may range from a minority position to 100 percent ownership. Proposed
investments may be made in either quoted or unquoted companies and structured as
a direct acquisition, joint venture or as a direct interest in a project.

The Company has made investments and will seek further investment opportunities 
that can be developed through the investment of capital or where part of or all 
of the consideration could be satisfied by the issue of new Ordinary Shares or other
securities in the Company. The investments the Company has made and any new opportunities
have, or would generally have, some or all of the following characteristics, namely:

·      a majority of their revenue derived from IT or the use of IT, and strongly
positioned to benefit from market growth;

·      a trading history which reflects past profitability or potential for significant
capital growth going forward; and

·      where all or part of the consideration could be satisfied by the issue of
new Ordinary Shares or other securities in the Company.

The Company will identify and assess potential investment targets and where it believes
further investigation is required, intends to appoint appropriately qualified advisers
to assist.

The Company proposes to carry out a comprehensive and thorough project review process
in which all material aspects of any potential investment will be subject to rigorous
due diligence, as appropriate. It is likely that the Company’s financial resources
will be invested in a small number of projects or investments.

The Tern’s investing policy is also available on the Company’s website.

**Portfolio Companies and Holdings as at 31 December 2024**

**Device Authority Limited** **(“DA” or “Device Authority”)**

_Valuation: £4.3m_ **(**_31 December 2023: £4.4m)_

_Equity ownership__: 25.3_% _(before any dilution on exercise of share options)_

Device Authority, a recognised global leader in Identity and Access Management (
IAM) for the Internet of Things (IoT), has continued to build strong business momentum
in 2024.

At the core of its success are the company’s flagship solutions-KeyScaler® and KeyScaler
Edge®-which provide comprehensive, end-to-end security lifecycle management across
the Edge-to-Enterprise continuum. These solutions integrate seamlessly with leading
IoT cloud platforms including Microsoft Azure, Avnet IoTConnect, AWS, PTC ThingWorx,
and Google Cloud, enabling robust, scalable security for both new and legacy IoT
deployments.

Device Authority is seeking to shape the future of connected systems through automated
Zero Trust security at scale. As a global IAM leader for Enterprise IoT, the company
serves critical industries such as Industrial, Automotive, Healthcare, and Critical
Infrastructure.

The company’s KeyScaler-as-a-Service (KSaaS®) platform empowers organisations to
minimise risk, reduce human error, and accelerate incident response, allowing organisations
to establish trust in every device and data transaction. With the addition of KeyScaler
AI, Device Authority now also enables secure and trusted AI in any connected environment.

This cloud-first, automation-driven approach has fuelled a strong start to the year,
with new blue-chip customers onboarded and multiple enterprise-level Proof of Concept
and pilot initiatives underway. Enterprises are increasingly choosing Device Authority
for its cost-effective scalability and rapid automation-capable of authenticating,
certifying, and registering devices in under 10 seconds, 60 times faster than manual
methods.

Device Authority’s expanding partner ecosystem remains a strategic focus, with new
collaborations including PlaxidityX (formerly Argus) and CyberArk, alongside a deepening
partnership with Microsoft, which named Device Authority as a key component of its
next-generation automotive and mobility security initiative.

The company’s innovation and leadership have earned widespread industry recognition,
including:

·      IoThinkTank’s IoT Security Product of the Year

·      IoT HealthTech Innovation Award

·      IoTSF’s IoT Security Champion Award

Additionally, Device Authority has been named a Leader in the Quadrant Knowledge
Solutions Spark Matrix for IoT IAM for the fifth consecutive year, achieving the
highest ranking in Technology Excellence.

**FVRVS Limited** **(“FundamentalVR”)**

_Valuation: £3.6m_ (_31 December 2023: £3.6m)_

_Equity ownership: 10.3%_ _(before any dilution on exercise of share options)_

FundamentalVR is a pioneering platform at the intersection of virtual reality, haptics,
and data analytics, led by surgical education experts and top technologists. With
a mission to revolutionise global surgical education, the company is making high-
fidelity simulation both accessible and affordable, equipping medical professionals
worldwide with state-of-the-art training tools.

The platform utilises widely available VR hardware-such as Meta’s Oculus Quest-and
integrates advanced haptics technology to deliver a highly realistic, tactile simulation
experience. Designed to operate seamlessly on standard computing systems, FundamentalVR
provides surgeons with immersive, hands-on practice that closely mirrors real-life
procedures, significantly enhancing preparedness and patient outcomes.

The platform’s impact is supported by recent findings published in the Journal of
Robotic Surgery, which highlighted the benefits of immersive VR training. The study
reported positive outcomes when trainees used the FVR’s system in an operating room
setting with CMR Surgical’s Versius robot-a long-standing FundamentalVR partner.

In 2024, FundamentalVR expanded its influence in the medical device sector through
strategic partnerships and product innovation. The integration of the platform with
Apple Vision Pro and Logitech’s Stylus MX INK has further strengthened its leadership
in immersive training and spatial computing. These advancements have not only enhanced
the realism of the simulation experience but also solidified the platform’s position
as an industry frontrunner.

Continuing its commitment to innovation, the company is also investing in Generative
AI. It recently introduced Maia, a virtual AI-powered tutor embedded in the Fundamental
Surgery Immersive VR Platform, designed to guide and support learners throughout
their training journey. Maia marks a significant leap forward in personalised, adaptive
surgical education.

With its award-winning technology, growing recognition, and focus on cutting-edge
innovation, FundamentalVR is setting a new standard in surgical training for the
digital age.

**Talking Medicines Limited** **(“Talking Medicines”)**

_Valuation: £2.1m_ _(31 December 2023: £2.0m)_

_Equity ownership: 23.8%_ _(before any dilution on exercise of share options)_

Talking Medicines, a pioneering force in healthcare intelligence powered by Advanced
Data Science and Artificial Intelligence, demonstrated significant progress in the
first half of 2024 through the growing success of its flagship interface, Drug-GPT.
Headquartered in Glasgow, the company continues to expand its commercial footprint
in the U.S., with a growing presence across New Jersey, New York, and Philadelphia.

Drug-GPT has attracted considerable attention and revenue from leading global healthcare
advertising agencies, which recognise its potential to revolutionise pharmaceutical
marketing strategies. With U.S. pharmaceutical companies spending more than $30 
billion annually on drug marketing, the appetite for transformative tools is strong-
particularly amid 2024’s trends, including the industry shifting toward personalised
medicine and the rapid adoption of Generative AI. These changes are driving a departure
from outdated insight methods, such as focus groups, toward AI-powered platforms
capable of delivering targeted, high-quality intelligence at scale.

Offering a validated 80% uplift in productivity, Drug-GPT significantly enhances
efficiency in data curation and strategic insight generation. By aggregating and
interpreting conversations from patients and healthcare professionals, the platform
unlocks previously inaccessible data insights, enabling pharmaceutical clients to
make better-informed, data-driven decisions.

Talking Medicines works with some of the world’s largest healthcare ad agency networks,
underscoring the value and credibility of Drug-GPT. The company continues to both
onboard new clients and expand its footprint within existing partnerships, fueling
the steady growth of its U.S. client base, with further expansion anticipated through
the remainder of 2025.

Strategic partnerships remain central to Talking Medicines’ success-both in sourcing
raw data from health data communities and in deepening collaboration with clients
seeking competitive advantages in an evolving landscape. Drug-GPT is continuously
evolving, guided by the company’s in-house data science team.

As part of its commitment to advancing industry understanding, Talking Medicines
continues to contribute to academic discourse, most recently publishing a comparative
study on patient language across therapeutic domains. These ongoing R&D efforts 
not only enrich the company’s scientific credibility but also strengthen the intellectual
property moat around its proprietary use of AI and data science in healthcare.

Looking ahead, Talking Medicines remains focused on expanding its customer base 
and U.S. market leadership, with ambitions to become the go-to partner for patient
and healthcare practitioner intelligence. The company’s management believes upcoming
enhancements to Drug-GPT will continue to excite and engage clients, reinforcing
its position as a preferred provider for AI-powered healthcare marketing intelligence.

**Sure Valley Ventures Enterprise Capital LP (“SVV2”)**

_Valuation: £0.3m_ _(31 December 2023: £0.1m)_

_Equity ownership: 6.1%_

SVV2 is a leading venture capital fund investing in a diverse range of private UK
software companies, with a strong focus on the rapidly growing immersive technology
and metaverse sectors. Its portfolio includes ventures specialising in augmented
and virtual reality, artificial intelligence, and cybersecurity.

SVV2’s investment journey began with a £1m investment in RETìníZE Limited in March
2022, followed by a £500k follow-on investment in this company in 2024. In November
2022, the Fund invested £1.05m in Jaid (Opsmatix Limited), later adding £800k in
tranches. September 2023 saw a £1.5m investment in Captur, an AI-driven workflow
automation firm. In 2024, SVV2 made five new investments: £750k in Vortex IQ (June),
£650k in Ittybit (June),

£1m in Phinxt Robotics (July), £1.5m in Purple Transform and £500k in Stylus Education(
both August), and £1m in Vizgard (December), with £500k funded upfront and an option
for another £500k investment.

Looking ahead, 2025 is set to be SVV2’s largest deployment year yet, targeting 6-
8 new investments and further portfolio expansions, with drawdowns of 15-20% of 
SVV2.

**Diffusiondata (previously Push Technology)**

_Valuation: £0.02m_ _(31 December 2023: £0.02m)_

_Equity ownership: <1%_

DiffusionData enhances organisations’ ability to facilitate real-time communication,
extending beyond direct interactions to include automatic data updates across various
channels. Its technology ensures that displayed information refreshes instantly-
without user intervention-enabling seamless, dynamic experiences.

This real-time responsiveness is crucial for interactive applications, making them
more engaging and efficient as they automatically adapt to new data the moment it
becomes available.

**Wyld Networks AB (publ)** (“Wyld Networks” or “Wyld”)

_Valuation: £0.003m_ **(**_31 December 2023: £2.4m)_

_Holding: 0.6%_

Wyld Networks, listed on the NASDAQ First North Growth Market in Stockholm, is seeking
to transform global connectivity by delivering affordable wireless solutions in 
regions where conventional coverage is unavailable or congested. Specialising in
satellite-based IoT communications, the company’s flagship solution, Wyld Connect,
enables seamless data transmission between IoT sensors and low Earth orbit (LEO)
satellites via compact terminals and modules.

Wyld Networks achieved continued customer acquisition growth and marked a significant
milestone with the commercial launch of its L-Band product. This development is 
key to delivering truly global IoT connectivity, expanding the company’s service
capabilities to even more remote and underserved locations.

Wyld successfully launched a satellite-enabled IoT tracker, aimed initially at tracking
moving assets-a valuable solution for sectors such as logistics, agriculture, and
conservation.

Wyld also secured several strategic partnerships and deployments:

·    In Brazil, the company partnered with GeoApis to monitor bee colonies using
LEO satellite connectivity, aiming to enhance pollination efficiency, [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news),
and crop yields.

·    With SugaROx, a UK-based innovator in biostimulants, Wyld is supporting agricultural
productivity and climate resilience in Brazil through enhanced field monitoring.

·    In the UK, Wyld entered into a collaboration with Harper Adams University, 
a leading institution in agriculture and environmental sciences, to deliver soil
moisture data for cabbage crops across its 550-hectare research facility in Shropshire.

Additionally, Wyld forged a key partnership with Actility, a global leader in IoT
connectivity platforms. This collaboration integrates Wyld’s satellite capabilities
with ThingPark Exchange, Actility’s premier LoRaWAN® peering hub, enabling broader
interoperability and global scalability for IoT applications.

From a commercial standpoint, Wyld Networks has concentrated efforts in South America,
North America, Africa, and the Middle East, and has recently initiated expansion
into the Asia-Pacific region, starting with Australia.

Wyld experienced financial difficulties during the year and was forced to raise 
additional funds, via a rights issue, under what the Board considered to be unfavorable
terms. This rights issue involved issuing a large number of new shares at a low 
price, which significantly diluted the value of existing shares. Tern chose not 
to participate in the funding rights issue, which led to a substantial reduction
in its ownership stake. The highly dilutive nature of the equity issue caused Wyld’s
share price to fall sharply, and it has remained depressed since.

**Availability of Annual Report**

The annual report for the year ended 31 December 2024 will shortly be available 
from the Company’s website https://www.ternplc.com/investors  and will shortly be
posted to shareholders.

Details of the Company’s 2025 Annual General Meeting will be announced separately

Share on:
